.jpg)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Celldex (CLDX) today and set a price target of $19. The company’s shares closed on Friday at $3.04, close to its 52-week low of $2.75.
Pantginis commented:
“Valuation and risks to price target achievement. We maintain our Buy rating and $19 price target. Our target is based on our clinical net present value (NPV) model, which currently derives its value from CDX-1140, CDX-3379, and varlilumab.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -5.1% and a 33.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Celldex has an analyst consensus of Moderate Buy, with a price target consensus of $19.
See today’s analyst top recommended stocks >>
Based on Celldex’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $17.24 million. In comparison, last year the company had a GAAP net loss of $118 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.
